Hearing loss often triggers an inescapable buzz (tinnitus) and causes everyday sounds to become intolerably loud (hyperacusis), but exactly where and how this occurs in the brain is unknown. To identify the neural substrate for these debilitating disorders, we induced both tinnitus and hyperacusis with an ototoxic drug (salicylate) and used behavioral, electrophysiological, and functional magnetic resonance imaging (fMRI) techniques to identify the tinnitus-hyperacusis network. Salicylate depressed the neural output of the cochlea, but vigorously amplified sound-evoked neural responses in the amygdala, medial geniculate, and auditory cortex. Resting-state fMRI revealed hyperactivity in an auditory network composed of inferior colliculus, medial geniculate, and auditory cortex with side branches to cerebellum, amygdala, and reticular formation. Functional connectivity revealed enhanced coupling within the auditory network and segments of the auditory network and cerebellum, reticular formation, amygdala, and hippocampus. A testable model accounting for distress, arousal, and gating of tinnitus and hyperacusis is proposed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4426664 | PMC |
http://dx.doi.org/10.7554/eLife.06576 | DOI Listing |
Comput Biol Med
December 2024
École de technologie supérieure, 1100 Notre-Dame St W, Montreal, H3C 1K3, Quebec, Canada; Centre for Interdisciplinary Research in Music Media and Technology (CIRMMT), 527 Rue Sherbrooke O #8, Montréal, QC H3A 1E3, Canada. Electronic address:
Background: Although stress plays a key role in tinnitus and decreased sound tolerance, conventional hearing devices used to manage these conditions are not currently capable of monitoring the wearer's stress level. The aim of this study was to assess the feasibility of stress monitoring with an in-ear device.
Method: In-ear heartbeat sounds and clinical-grade electrocardiography (ECG) signals were simultaneously recorded while 30 healthy young adults underwent a stress protocol.
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Federal Center of Brain Research and Neurotechnologies, Moscow, Russia.
According to the literature, a number of anti-epileptic drugs (AEDs) have an ototoxic effect. The mechanism of hearing dysfunction due to the use of AEDs is not well known. The main clinical manifestations of the cochleotoxic effect of the drugs are: tinnitus, sensorineural hearing loss, impaired pitch perception, hyperacusis.
View Article and Find Full Text PDFJ Assoc Res Otolaryngol
December 2024
Newcastle University Medical School, Newcastle Upon Tyne, NE2 4HH, UK.
Due to the heterogeneous causes, symptoms and associated comorbidities with tinnitus, there remains an unmet need for a clear biomarker of tinnitus presence. Previous research has suggested a "final pathway" of tinnitus presence, which occurs regardless of the specific mechanisms that resulted in alterations of auditory predictions and, eventually, tinnitus perception. Predictive inference mechanisms have been proposed as the possible basis for this final unifying pathway.
View Article and Find Full Text PDFEye (Lond)
December 2024
Center for Ophthalmic Bioinformatics, Cleveland Clinic, Cole Eye Institute, Cleveland, OH, USA.
Background/objectives: Patients with thyroid eye disease (TED) taking teprotumumab have reported audiologic symptoms as a side effect; however, limited real world data and large sample sizes have been utilized to evaluate this relationship.
Methods: A retrospective cohort study was created in TriNetX to identify patients with TED utilizing ICD-10, CPT, and Healthcare Common Procedure coding systems. TED patients with and without teprotumumab treatment were analysed with greedy one-to-one propensity matching.
Otol Neurotol
January 2025
Cedars-Sinai Medical Center, Division of Otolaryngology-Head and Neck Surgery, Los Angeles, CA.
Introduction: GLP-1 receptor agonists (GLP-1 RAs) have gained traction in the management of obesity. There is limited literature on the implications of GLP-1 RAs in the field of otolaryngology.
Methods: We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!